Prenetics Global (NASDAQ:PRE) Raised to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Prenetics Global from “sell” to “hold.” The broader analyst consensus is “Moderate Buy,” with four Buy ratings, one Sell rating, and an average price target of $34.25.
• Prenetics reported a quarterly EPS loss of $0.53, better than the expected $0.84 loss, but revenue of $46.49 million fell short of the $49.85 million estimate. The company remains unprofitable, with a negative net margin of 47.43%.
• IM8 growth is a major potential catalyst: second-quarter revenue rose 288% year over year, prompting higher 2026 guidance of $220 million–$230 million and initial 2027 guidance of at least $400 million. However, mixed earnings forecasts and continued projected losses highlight ongoing profitability risks.

Prenetics Global (NASDAQ:PRE - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

A number of other research analysts have also weighed in on the stock. Benchmark raised their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Prenetics Global in a research note on Friday, July 17th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $34.25.

Prenetics Global Stock Performance

NASDAQ:PRE opened at $20.20 on Friday. The stock has a market capitalization of $340.85 million, a PE ratio of -4.86 and a beta of 0.26. Prenetics Global has a fifty-two week low of $7.18 and a fifty-two week high of $23.63. The company has a fifty day moving average of $19.05 and a two-hundred day moving average of $18.88.

Prenetics Global (NASDAQ:PRE - Get Free Report) last announced its earnings results on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.31. The business had revenue of $46.49 million for the quarter, compared to analyst estimates of $49.85 million. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. Research analysts forecast that Prenetics Global will post -1.86 earnings per share for the current year.

Institutional Investors Weigh In On Prenetics Global

Large investors have recently modified their holdings of the business. Jane Street Group LLC acquired a new position in Prenetics Global during the fourth quarter worth about $1,302,000. 683 Capital Management LLC purchased a new position in Prenetics Global in the 4th quarter worth approximately $1,181,000. Millennium Management LLC acquired a new position in shares of Prenetics Global during the 4th quarter worth approximately $810,000. Marshall Wace LLP acquired a new position in shares of Prenetics Global during the 4th quarter worth approximately $788,000. Finally, UBS Group AG grew its position in shares of Prenetics Global by 581.9% in the third quarter. UBS Group AG now owns 46,561 shares of the company's stock valued at $619,000 after purchasing an additional 39,733 shares in the last quarter. Hedge funds and other institutional investors own 25.01% of the company's stock.

Key Stories Impacting Prenetics Global

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: IM8 reported 288% year-over-year revenue growth in the second quarter and Prenetics raised its FY 2026 IM8 revenue guidance to $220 million–$230 million. The company also initiated FY 2027 revenue guidance of at least $400 million, signaling strong expected demand and expansion. IM8 Q2 revenue growth and guidance article
• Positive Sentiment: Prenetics announced actress and producer Lily Collins as IM8’s global ambassador and a shareholder. Her audience of more than 33 million social-media followers could broaden IM8’s reach beyond elite sports and improve its access to female consumers. The company said it has already achieved positive consolidated adjusted free cash flow and expects to remain positive in the third quarter. Lily Collins IM8 partnership article
• Neutral Sentiment: Analyst forecasts are mixed. Sidoti raised its Q3 and Q4 2026 estimates but still projects a FY 2026 loss of $2.36 per share, while Zacks lowered its Q3 2026 and FY 2026 forecasts but expects stronger Q4 results and a narrower Q1 2027 loss. These revisions suggest near-term volatility as investors assess whether IM8’s growth can translate into sustained profitability.
• Negative Sentiment: Sidoti lowered its FY 2027 EPS forecast to a loss of $0.72 from a loss of $0.60 and reduced several 2027 quarterly estimates. Prenetics’ latest quarter also showed a negative net margin, and revenue was below consensus despite an EPS beat, underscoring execution and profitability concerns.

Prenetics Global Company Profile

Prenetics Global NASDAQ: PRE is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company's core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source